Royal Bank of Canada’s Intersect ENT, Inc XENT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
Sell
-4,009
Closed -$112K 8201
2022
Q1
$112K Sell
4,009
-106,476
-96% -$2.92M ﹤0.01% 5571
2021
Q4
$3.02M Buy
110,485
+17,086
+18% +$463K ﹤0.01% 2792
2021
Q3
$2.54M Buy
93,399
+84,619
+964% +$2.09M ﹤0.01% 2870
2021
Q2
$150K Buy
8,780
+558
+7% +$10.4K ﹤0.01% 5310
2021
Q1
$171K Buy
8,222
+1,430
+21% +$33K ﹤0.01% 5073
2020
Q4
$155K Buy
6,792
+94
+1% +$1.79K ﹤0.01% 5049
2020
Q3
$110K Sell
6,698
-45
-0.7% -$815 ﹤0.01% 4914
2020
Q2
$91K Buy
6,743
+436
+7% +$5.07K ﹤0.01% 4907
2020
Q1
$75K Sell
6,307
-1,846
-23% -$40.9K ﹤0.01% 4942
2019
Q4
$203K Sell
8,153
-5,115
-39% -$104K ﹤0.01% 4632
2019
Q3
$226K Sell
13,268
-291
-2% -$5.3K ﹤0.01% 4378
2019
Q2
$309K Sell
13,559
-893
-6% -$24.1K ﹤0.01% 4187
2019
Q1
$465K Buy
14,452
+6,631
+85% +$205K ﹤0.01% 3774
2018
Q4
$220K Sell
7,821
-197,139
-96% -$5.77M ﹤0.01% 4293
2018
Q3
$5.89M Sell
204,960
-10,119
-5% -$304K ﹤0.01% 1999
2018
Q2
$8.05M Buy
215,079
+99,976
+87% +$3.92M ﹤0.01% 1677
2018
Q1
$4.52M Buy
115,103
+86,239
+299% +$3.15M ﹤0.01% 2057
2017
Q4
$935K Buy
28,864
+11,852
+70% +$355K ﹤0.01% 3280
2017
Q3
$530K Sell
17,012
-1,014
-6% -$30K ﹤0.01% 3745
2017
Q2
$504K Sell
18,026
-2,334
-11% -$52.8K ﹤0.01% 3653
2017
Q1
$349K Sell
20,360
-848
-4% -$11.9K ﹤0.01% 3928
2016
Q4
$256K Buy
21,208
+1,858
+10% +$24.1K ﹤0.01% 4321
2016
Q3
$307K Sell
19,350
-27,000
-58% -$407K ﹤0.01% 4117
2016
Q2
$599K Buy
46,350
+46,250
+46,250% +$724K ﹤0.01% 3544
2016
Q1
$2K Sell
100
-713
-88% -$12.9K ﹤0.01% 6156
2015
Q4
$18K Sell
813
-6,093
-88% -$120K ﹤0.01% 5761
2015
Q3
$161K Buy
6,906
+2,036
+42% +$56.2K ﹤0.01% 4482
2015
Q2
$139K Buy
4,870
+757
+18% +$19.8K ﹤0.01% 4632
2015
Q1
$106K Buy
4,113
+4,055
+6,991% +$92.7K ﹤0.01% 4592
2014
Q4
$1K Buy
+58
New +$1.04K ﹤0.01% 6071

Royal Bank of Canada's XENT Position: Q2 2022 in Review

Royal Bank of Canada sold out of Intersect ENT, Inc (XENT) in Q2 2022, closing a stake of 4,009 shares — an estimated $112K sold.

Royal Bank of Canada first reported a position in XENT in Q4 2014 and held it in 30 quarters. The position peaked at $8.05M in Q2 2018. 0 funds tracked by Wall St. Rank hold XENT as of Q2 2022.

  • Royal Bank of Canada reported no remaining Intersect ENT, Inc position as of Q2 2022 after selling out during the quarter.
  • Royal Bank of Canada sold 4,009 Intersect ENT, Inc shares in Q2 2022, an estimated $112K.
  • Royal Bank of Canada first reported a position in Intersect ENT, Inc in Q4 2014 and held it in 30 quarters.
  • Royal Bank of Canada's Intersect ENT, Inc position peaked at $8.05M in Q2 2018.
  • 0 funds tracked by Wall St. Rank held Intersect ENT, Inc as of Q2 2022.

Based on Royal Bank of Canada's 13F filing for Q2 2022, filed 15 Aug 2022.